These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18678840)

  • 1. Summaries for patients. Screening for prostate cancer with prostate-specific antigen testing: U.S. Preventive Services Task Force recommendations.
    Ann Intern Med; 2008 Aug; 149(3):I37. PubMed ID: 18678840
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    U.S. Preventive Services Task Force
    Ann Intern Med; 2008 Aug; 149(3):185-91. PubMed ID: 18678845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.
    Lin K; Lipsitz R; Miller T; Janakiraman S;
    Ann Intern Med; 2008 Aug; 149(3):192-9. PubMed ID: 18678846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries for patients. Screening for prostate cancer: a recommendation from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2002 Dec; 137(11):I48. PubMed ID: 12459001
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force.
    Am J Prev Med; 1994; 10(4):187-93. PubMed ID: 7528518
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries for patients. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Ann Intern Med; 2012 Jul; 157(2):I-44. PubMed ID: 22801691
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
    Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
    Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
    Schröder FH
    N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
    Catalona WJ; D'Amico AV; Fitzgibbons WF; Kosoko-Lasaki O; Leslie SW; Lynch HT; Moul JW; Rendell MS; Walsh PC
    Ann Intern Med; 2012 Jul; 157(2):137-8. PubMed ID: 22801676
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Roobol MJ; Schröder FH
    J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
    Brett AS; Ablin RJ
    N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA test not recommended by Canadian Task Force.
    Tanday S
    Lancet Oncol; 2014 Dec; 15(13):e589. PubMed ID: 25499287
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer. When to offer screening in the primary care setting.
    Gambert SR
    Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough.
    Wroclawski ML
    Einstein (Sao Paulo); 2017; 15(3):7-10. PubMed ID: 29091165
    [No Abstract]   [Full Text] [Related]  

  • 18. Screening for prostate cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 Mar; 103(3):107-10; discussion 111. PubMed ID: 12626949
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--counterpoint.
    Catalona WJ
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):395-7. PubMed ID: 22315363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.